Financials

News Ideas Discussions Forecast Seasonals

X2S fundamentals

Overview Statements Statistics Dividends Earnings Revenue

An in-depth look to SINOPHARM GRP CO. H YC 1 operating, investing, and financing activities

X2S free cash flow for H1 24 is -5.59 B EUR. For 2023, X2S free cash flow was 1.49 B EUR and operating cash flow was 1.75 B EUR.

Cash from operating activities

Cash from investing activities

Cash from financing activities

Income statement Balance sheet Cash flow

Currency: EUR

TTM

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—